1h Free Analyst Time
The publisher's latest Pharmaceutical and Healthcare disease pipeline guide Type 2 Diabetes - Drugs In Development, 2022, provides an overview of the Type 2 Diabetes (Metabolic Disorders) pipeline landscape.Speak directly to the analyst to clarify any post sales queries you may have.
Type 2 diabetes is a chronic condition and is the most common form of diabetes. High levels of glucose are a characteristic feature. The body might become resistant to insulin or may not produce enough amounts. Due to abnormal insulin functioning, glucose is concentrated in the blood leading to elevated levels and hence causing type 2 diabetes. Symptoms include fatigue, weight issues, vision deficits and various other effects. Risk factors include family history, age, obesity, physical inactivity and high blood pressure. This condition is handled by lifestyle alterations and regular medications.
Report Highlights
The publisher's Pharmaceutical and Healthcare latest pipeline guide Type 2 Diabetes - Drugs In Development, 2022, provides comprehensive information on the therapeutics under development for Type 2 Diabetes (Metabolic Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.The Type 2 Diabetes (Metabolic Disorders) pipeline guide also reviews of key players involved in therapeutic development for Type 2 Diabetes and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Pre-Registration, Filing rejected/Withdrawn, Phase III, Phase II, Phase I, Phase 0, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 13, 2, 69, 74, 113, 3, 32, 267, 66 and 13 respectively. Similarly, the Universities portfolio in Phase I, IND/CTA Filed, Preclinical and Discovery stages comprises 2, 2, 60 and 16 molecules, respectively.
Type 2 Diabetes (Metabolic Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from the publisher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
Scope
- The pipeline guide provides a snapshot of the global therapeutic landscape of Type 2 Diabetes (Metabolic Disorders).
- The pipeline guide reviews pipeline therapeutics for Type 2 Diabetes (Metabolic Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Type 2 Diabetes (Metabolic Disorders) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Type 2 Diabetes (Metabolic Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Type 2 Diabetes (Metabolic Disorders)
Reasons to Buy
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Type 2 Diabetes (Metabolic Disorders).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Type 2 Diabetes (Metabolic Disorders) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table of Contents
- Introduction
- Report Coverage
- Type 2 Diabetes - Overview
- Type 2 Diabetes - Therapeutics Development
- Pipeline Overview
- Pipeline by Companies
- Pipeline by Universities/Institutes
- Products under Development by Companies
- Products under Development by Universities/Institutes
- Type 2 Diabetes - Therapeutics Assessment
- Assessment by Target
- Assessment by Mechanism of Action
- Assessment by Route of Administration
- Assessment by Molecule Type
- Type 2 Diabetes - Companies Involved in Therapeutics Development
- Type 2 Diabetes - Drug Profiles
- Type 2 Diabetes - Dormant Projects
- Type 2 Diabetes - Discontinued Products
- Type 2 Diabetes - Product Development Milestones
- Featured News & Press Releases
- Appendix
- Methodology
- Coverage
- Secondary Research
- Primary Research
- Expert Panel Validation
- Contact the Publisher
- Disclaimer
- Number of Products under Development for Type 2 Diabetes, 2022
- Number of Products under Development by Companies, 2022
- Number of Products under Development by Universities/Institutes, 2022
- Products under Development by Companies, 2022
- Products under Development by Universities/Institutes, 2022
- Number of Products by Stage and Target, 2022
- Number of Products by Stage and Mechanism of Action, 2022
- Number of Products by Stage and Route of Administration, 2022
- Number of Products by Stage and Molecule Type, 2022
- Type 2 Diabetes - Dormant Projects, 2022
- Type 2 Diabetes - Discontinued Products, 2022
- Number of Products under Development for Type 2 Diabetes, 2022
- Number of Products under Development by Companies, 2022
- Number of Products under Development by Universities/Institutes, 2022
- Number of Products by Top 10 Targets, 2022
- Number of Products by Stage and Top 10 Targets, 2022
- Number of Products by Top 10 Mechanism of Actions, 2022
- Number of Products by Stage and Top 10 Mechanism of Actions, 2022
- Number of Products by Top 10 Routes of Administration, 2022
- Number of Products by Stage and Top 10 Routes of Administration, 2022
- Number of Products by Top 10 Molecule Types, 2022
- Number of Products by Stage and Top 10 Molecule Types, 2022
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- 3SBio Inc
- Abarceo Pharma AB
- Adare Pharma Solutions
- Addpharma Inc
- Adocia SAS
- Aerami Therapeutics Inc
- Afimmune Biopharma Ltd
- Agentix Corp
- AgeX Therapeutics Inc
- Aju Pharm Co Ltd
- Akero Therapeutics Inc
- Akston Biosciences Corp
- Algiax Pharmaceuticals GmbH
- Alms Therapeutics
- Alnylam Pharmaceuticals Inc
- AlphaMab Co Ltd
- Alphamab Oncology
- Altimmune Inc
- AltrixBio Inc
- Amide Technologies Inc
- AmideBio, LLC
- Amogen Pharma Pvt Ltd
- Anagenesis Biotechnologies SAS
- Ananda Scientific Inc
- Anji Pharmaceuticals Inc
- AnyGen Co Ltd
- Anyuan Pharmaceutical Technology (Shanghai) Co Ltd
- Apcegen Technologies Pvt Ltd
- Aphios Corp
- Apoglyx AB
- APT Therapeutics Inc
- Aptamer Sciences Inc
- AptamiR Therapeutics Inc
- Arecor Therapeutics Plc
- Ariddad Therapeutics SL
- Arkay Therapeutics LLC
- Artery Therapeutics Inc
- Asdera LLC
- Astellas Pharma Inc
- AstraZeneca Plc
- Atrogi AB
- Autotac Bio Inc
- Autotelic Bio Inc
- Avolynt Inc
- Beijing Eastern Biotech Co Ltd
- Beijing Northland Biotech Co Ltd
- Beijing QL Biopharmaceutical Co Ltd
- Beijing SL Pharmaceutical Co Ltd
- Belite Bio Inc
- Betagenon AB
- Betta Pharmaceuticals Co Ltd
- Biocon Ltd
- BioEos Ltd
- Biogenomics Ltd
- BioKier Inc
- BioLingus AG
- Biomea Fusion Inc
- Biora Therapeutics Inc
- BioRestorative Therapies Inc
- Biotts SA
- Biozeus Pharmaceutical SA
- Boehringer Ingelheim International GmbH
- Bopin (Shanghai) Biomedical Technology Co Ltd
- Boryung Pharmaceutical Co Ltd
- Braasch Biotech LLC
- BrightGene Bio-Medical Technology Co Ltd
- C4X Discovery Holdings Plc
- Caelus Health
- Caldan Therapeutics Ltd
- CAR-T (Shanghai) Biotechnology Co Ltd
- Carlina Technologies SAS
- Carmot Therapeutics Inc
- Celdara Medical LLC
- Cellebration Life Sciences Inc
- Cellix Bio Pvt Ltd
- Celon Pharma SA
- Centaurus Therapeutics Inc
- Center Laboratories Inc
- CGeneTech (Suzhou China) Co Ltd
- Chain Biotechnology Ltd
- Chengdu Di'ao Pharmaceutical Group Co Ltd
- Chengdu Easton Biopharmaceuticals Co Ltd
- Chengdu Shengdi Medical Company Co Ltd
- Chong Kun Dang Pharmaceutical Corporation
- Chongqing Chenan BioPharm Co Ltd
- Cinnagen Co
- Cisen Pharmaceutical Co Ltd
- CMG Pharmaceutical Co Ltd
- CohBar Inc
- Concenter BioPharma Silkim Ltd
- ConjuChem LLC
- CRISPR Therapeutics AG
- CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co Ltd
- D&D Pharmatech Co Ltd
- Daewon Pharmaceutical Co Ltd
- Daewoo Pharmaceutical Co Ltd
- Daewoong Pharmaceutical Co Ltd
- Daiichi Sankyo Co Ltd
- Dale Biotech LLC
- Delpor Inc
- Diabetology (Products) Ltd
- Diamyd Medical AB
- Diapin Therapeutics LLC
- Diasome Pharmaceuticals Inc
- DiscoveryBiomed Inc
- DNJ Pharma Inc
- DNX Biopharmaceuticals Inc
- Dong Wha Pharma Co Ltd
- Dong-A Socio Holdings Co Ltd
- Dong-A ST Co Ltd
- DongKoo Bio & Pharma Co Ltd
- EastGate Pharmaceuticals Inc
- Eccogene (Shanghai) Co Ltd
- Efil Bioscience Inc
- Egy-Nano Pharma LP
- Elevian Inc
- Eli Lilly and Co
- Emmaus Life Sciences Inc
- Empros Pharma AB
- EncuraGen Co Ltd
- Enesi Pharma Ltd
- Enteris BioPharma Inc
- Enzene Biosciences Ltd
- Enzo Biochem Inc
- Epichem Pty Ltd
- Eternygen GmbH
- Evotec SE
- F. Hoffmann-La Roche Ltd
- Fochon Pharmaceutical Ltd
- Forkhead BioTherapeutics Inc
- FortuneRock (China) Ltd
- Fujian Haixi New Medicine Creation Co Ltd
- Gan & Lee Pharmaceuticals Co Ltd
- Generex Biotechnology Corp
- Genexine Inc
- Genovate Biotechnology Co LTD
- Genprex Inc
- George Medicines Pty Ltd
- Geropharm
- GL Pharm Tech Corp
- Glaceum Inc
- Glucox Biotech AB
- Glyscend Inc
- Gmax Biopharm LLC
- Guangdong Zhongsheng Pharmaceutical Co Ltd
- Guangzhou Magpie Pharmaceutical Co Ltd
- Gubra ApS
- Guizhou Zhongguan Biotechnology Co Ltd
- Gusto Global LLC
- Hangzhou East China Pharmaceutical Group Co Ltd
- Hangzhou Jiuyuan Gene Engineering Co Ltd
- Hanmi Pharmaceuticals Co Ltd
- HCW Biologics Inc
- HEC Pharm Group
- HEC Pharma Co Ltd
- Hefei Industrial Pharmaceutical Institute Co Ltd
- HighTide Therapeutics Inc
- HK inno.N Corp
- Housey Pharmaceutical Research Laboratories LLC
- Hua Medicine Shanghai Ltd
- Huadong Medicine Co Ltd
- Hualan Biological Engineering Inc
- Huons Co Ltd
- Hyundai Pharma Co Ltd
- i2O Therapeutics Inc
- Ildong Pharmaceutical Co Ltd
- Imagine Pharma LLC
- Immunwork Inc
- Immupharma Plc
- Immuron Ltd
- Impetis Biosciences Ltd
- Inflammasome Therapeutics Inc
- Innovimmune Biotherapeutics Inc
- Intarcia Therapeutics Inc
- Integral Molecular Inc
- Inventiva SA
- Inversago Pharma Inc
- Ionis Pharmaceuticals Inc
- Japan Tobacco Inc
- Jeil Pharmaceutical Co Ltd
- Jiangsu Chia-tai Tianqing Pharmaceutical Co Ltd
- Jiangsu Hansoh Pharmaceutical Group Co Ltd
- Jiangsu Hengrui Medicine Co Ltd
- Jiangsu Lianhuan Pharmaceutical Co Ltd
- Jiangsu Sinopep Allsino Biopharmaceutical Co Ltd
- Jiangsu T-mab BioPharma Co Ltd
- Johnson & Johnson
- Kadimastem Ltd
- Kallyope Inc
- Kaneq Bioscience Ltd
- Karyo Biologics LLC
- KB Biomed Inc
- Klotho Therapeutics Inc
- Kolmar Korea Co Ltd
- Korea Pharma Co Ltd
- Kriya Therapeutics Inc
- Kyorin Pharmaceutical Co Ltd
- Kyung Dong Co Ltd
- Laboratorios Silanes SA de CV
- Lannett Co Inc
- Lanzhou Institute of Biological Products Co Ltd
- Lead Discovery Center GmbH
- Lepu Medical Technology (Beijing) Co Ltd
- Levim Biotech LLP
- Lexicon Pharmaceuticals Inc
- LG Chem Ltd
- Ligand Pharmaceuticals Inc
- LipimetiX Development Inc
- Lisata Therapeutics Inc
- Livzon Pharmaceutical Group Co Ltd
- Lixte Biotechnology Holdings Inc
- Longevity Biotech Inc
- Lotus Pharmaceutical Co Ltd
- Luckwel Pharmaceuticals Inc
- Luye Pharma Group Ltd
- Lyndra Therapeutics Inc.
- Mankind Pharma Ltd
- MannKind Corp
- MD Healthcare Inc
- Medesis Pharma SA
- Medlab Clinical Ltd
- Melior Pharmaceuticals I Inc
- Merck & Co Inc
- Mesoblast Ltd
- Metabolic Solutions Development Company LLC
- Metabolys SAS
- Metacrine Inc
- Metynex Pharmaceuticals AB
- Mito BioPharm LLC
- Mitsubishi Tanabe Pharma Corp
- Moderna Inc
- Moon (Guangzhou) Biological Technology Co Ltd
- MRM Health NV
- MThera Pharma Co Ltd
- MyMD Pharmaceuticals Inc
- Naia Ltd
- Neuraly Inc
- Neurimmune Holding AG
- Neurodon LLC
- NewG Lab Pharma Co Ltd
- NGM Biopharmaceuticals Inc
- NIMIUM Therapeutics Inc
- Ningbo Kunpeng Biotech Co Ltd
- Novartis AG
- NovMetaPharma Co Ltd
- Novo Nordisk AS
- NuSirt Biopharma Inc
- NutriBand Inc
- NVP Healthcare Co Ltd
- Oblique Therapeutics AB
- OliPass Corporation
- Omeros Corp
- Oncosimis Biotech Pvt Ltd
- OPKO Health Inc
- OptiKira LLC
- Oramed Pharmaceuticals Inc
- Original BioMedicals Co Ltd
- Overseas Pharmaceuticals Ltd
- Palatin Technologies Inc
- Palisade Bio, Inc
- Pano Therapeutics Inc
- Panorama Researchama Research
- Paras Biopharmaceuticals Finland Oy
- Park of Active Molecules
- PegBio Co Ltd
- Peptron Inc
- Pfizer Inc
- PharmaCyte Biotech Inc
- Pharmasaga Co Ltd
- Pila Pharma AB
- Polus Inc
- Poxel SA
- Preveceutical Medical Inc
- PrimeGen Global Inc
- Prokidney Corp
- ProLynx LLC
- Prometheon Pharma LLC
- ProMIS Neurosciences Inc
- Protheragen Inc
- Protibea Therapeutics Inc
- Prous Institute for Biomedical Research SA
- Purzer Pharmaceutical Co Ltd
- Qilu Regor Therapeutics Inc
- Qoracle Co Ltd
- QuiaPEG Pharmaceuticals AB
- Ramino-Bio Ltd
- Rani Therapeutics LLC
- Rebus Holdings Inc
- Regenerative Medical Solutions Inc
- Remd Biotherapeutics Inc
- Remedium Bio Inc
- reMYND NV
- Renova Therapeutics Inc
- Retinset SL
- Ridgeline Therapeutics LLC
- Rivus Pharmaceuticals Inc
- RosVivo Therapeutics Inc
- Samik Pharmaceutical Co Ltd
- Samjin Pharm Co Ltd
- Sanofi
- Sanwa Kagaku Kenkyusho Co Ltd
- ScandiCure AB
- Sciwind Biosciences Co Ltd
- Scohia Pharma Inc
- Senseion Inc
- Sensulin LLC
- Seoul Pharma Co Ltd
- Serodus ASA
- Serpin Pharma LLC
- Shaanxi Micot Technology Co Ltd
- Shandong Baijidichang Pharmaceutical Co Ltd
- Shandong Luye Pharmaceutical Co Ltd
- Shanghai Benemae Pharmaceutical Corp
- Shanghai Fosun Pharmaceutical (Group) Co Ltd
- Shanghai HEP Pharmaceutical Co Ltd
- Shanghai Innogen Pharmaceutical Technology Co Ltd
- Shenzhen Chipscreen Biosciences Co Ltd
- Shenzhen Salubris Pharmaceuticals Co Ltd
- Shionogi & Co Ltd
- Shouyao Holding Co Ltd
- Sichuan Haisco Pharmaceutical Co Ltd
- Sihuan Pharmaceutical Holdings Group Ltd
- Sino Biopharmaceutical Ltd
- Sirona Biochem Corp
- SJT Molecular Research SL
- SK Chemicals Co Ltd
- Sosei Group Corp
- Sparrow Pharmaceuticals Inc
- Stelis Biopharma Ltd
- Structure Therapeutics Inc
- Sulfateq BV
- Sun Pharmaceutical Industries Ltd
- Sveikatal Inc
- SymbioCellTech LLC
- Synokem Pharmaceuticals Ltd
- Synthetic Biologics Inc
- Taisho Pharmaceutical Holdings Co Ltd
- Takeda Pharmaceutical Co Ltd
- Tasly Pharmaceutical Group Co Ltd
- Techfields Pharma Co Ltd
- The Healthy Aging Co
- The United Laboratories International Holdings Ltd
- Theertha Biopharma Pvt Ltd
- Theracos Inc
- Thermalin Inc
- Tonghua Dongbao Pharmaceutical Co Ltd
- Torrent Pharmaceuticals Ltd
- Transdermal Delivery Solutions Corp
- Transgene Biotek Ltd
- Transira Therapeutics LLC
- TTY Biopharm Co Ltd
- Twist Bioscience Corp
- UGISense AG
- Uni-Bio Science Group Ltd
- United Biomedical Inc
- USV Pvt Ltd
- Valin Technologies Ltd
- ViaCyte Inc
- Viking Therapeutics Inc
- vTv Therapeutics Inc
- Vybion Inc
- Wockhardt Ltd
- Wren Therapeutics Ltd
- Wuxi Hebang Biotechnology Co Ltd
- Xeris Biopharma Holdings Inc
- XL-protein GmbH
- XOMA Corp
- XuanZhu Biological Technology Co Ltd
- Yichang Hec Changjiang Pharmaceutical Co Ltd
- Yooyoung Pharm Co Ltd
- Youngene Therapeutics Co Ltd
- Yueyang Pharmaceutical Development (Guangzhou) Co Ltd
- Zealand Pharma AS
- Zhejiang Doer Biologics Corp
- Zhejiang Hisun Pharmaceutical Co Ltd
- Zhejiang HuaYang Pharmaceutical Co Ltd
- Zhuhai United Laboratories Co Ltd
- Zih Yuan Tang Biotechnology Co Ltd
- Zucara Therapeutics Inc
- Zydus Lifesciences Ltd
